Knightscope, Soligenix, and Genetic Technologies Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV
Knightscope, Soligenix, and Genetic Technologies Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / October 6, 2023 / RedChip Companies will air interviews with Knightscope, Inc. (NASDAQ:KSCP), Soligenix, Inc. (Nasdaq:SNGX), and Genetic Technologies Limited (ASX:GTG)(NASDAQ:GENE) on The RedChip Small Stocks Big Money Show, a sponsored program on Bloomberg TV, this Saturday, October 7, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
佛罗里达州奥兰多/ACCESSWIRE/2023 年 10 月 6 日/ RedChip Companies将于美国东部时间10月7日星期六晚上7点在彭博电视台赞助的节目《红筹股大钱秀》上播出对Knightscope, Inc.（纳斯达克股票代码：KSCP）、Soligenix, Inc.（纳斯达克股票代码：SNGX）和基因技术有限公司（澳大利亚证券交易所股票代码：GTG）（纳斯达克股票代码：GENE）的采访。据估计，彭博电视在美国有7300万个家庭中播出。
Access the interviews in their entirety at:
访问访谈的全部内容，请访问：
- Knightscope:
- Soligenix:
- Genetic Technologies:
- Knightscope：
- Soligenix：
- 遗传技术：
William Santana Li, CEO and Chairman of Knightscope, Inc., appears on the RedChip Small Stocks Big Money Show on Bloomberg TV to provide a corporate update. Knightscope is an advanced security technology company based in Silicon Valley that builds fully autonomous security robots that deter, detect, and report. The Company's groundbreaking technology has proven to help in fighting crime and providing security and public safety professionals unprecedented situational awareness. Knightscope's cost-effective security robots help secure the places you live, work, study and visit. The Company's long-term ambition is to make the United States of America the safest country in the world.
Knightscope, Inc. 首席执行官兼董事长威廉·桑塔纳·李出现在彭博电视台的RedChip Small Stocks Big Money Show上，提供了公司最新情况。Knightscope是一家总部位于硅谷的先进安全技术公司，致力于制造能够阻止、检测和报告的全自主安全机器人。事实证明，该公司的开创性技术有助于打击犯罪，并为安全和公共安全专业人员提供前所未有的态势感知能力。Knightscope 经济实惠的安全机器人可帮助保护您的生活、工作、学习和参观场所。该公司的长期目标是使美利坚合众国成为世界上最安全的国家。
Also appearing on the RedChip Small Stocks Big Money Show this week is Dr. Chris Schaber, CEO of Soligenix. Soligenix, a late-stage biopharmaceutical company, offers a robust pipeline of multiple fast-track and orphan-designated products with the potential for significant commercial returns of approximately $2 billion in global annual sales. Soligenix's late-stage clinical assets include HyBryte (SGX301), a photodynamic therapy for the treatment of cutaneous T-cell lymphoma (CTCL). The positive statistically significant results achieved in the Phase 3 study of HyBryte have been published in JAMA Dermatology, and the Company is preparing to meet with the FDA to discuss the design of the second confirmatory Phase 3 study. The estimated global market potential for HyBryte is $250 million, making it a significant commercial opportunity in an area of unmet medical need.
Soligenix首席执行官克里斯·沙伯博士也出现在本周的RedChip Small Stocks Big Money Show上。Soligenix是一家处于后期阶段的生物制药公司，提供多种快速通道和孤儿指定产品的强大产品线，全球年销售额有可能带来约20亿美元的可观商业回报。Soligenix的后期临床资产包括Hybryte（SGX301），这是一种用于治疗皮肤T细胞淋巴瘤（CTCL）的光动力疗法。HyBryte的3期研究中取得的具有统计学意义的积极结果已发表在《JAMA Dermatology》上，该公司正准备与美国食品药品管理局会面，讨论第二项确认性3期研究的设计。据估计，HyBryte的全球市场潜力为2.5亿美元，这使其成为医疗需求未得到满足的领域的重大商业机会。
The third interview is with Simon Morriss, CEO of Genetic Technologies. Genetic Technologies is executing a B2B commercialization strategy for its flagship geneType Multi-Risk test covering breast cancer, colorectal cancer, prostate cancer, ovarian cancer, coronary artery disease and Type-2 diabetes, a first-in-class test that can predict a person's risk in up to 70% of annual mortalities and morbidities before onset. Recently, the Company's assessments for Pancreatic Cancer, Melanoma, and Atrial Fibrillation, were authorized for sale in Australia by National Association of Testing Authority (NATA). Genetic Technologies also signed a precision medicine pilot with Gold Coast Private Hospital (GCPH), a member of Healthscope - Australia's largest private hospital network. Separately, the Company also recently announced a Medical Research Future Fund (MRFF) Genomics Health Futures Mission Grant has been awarded to a group of renowned national and international research and charity organizations. The grant will provide funding for the CASSOWARY Trial: a randomized controlled trial of the clinical utility and cost-effectiveness of a multi-cancer polygenic risk score in general practice. GTG is the National Research Partner for trial.
第三次采访是基因技术公司首席执行官西蒙·莫里斯。Genetic Technologies正在为其旗舰GeneType多风险测试执行B2B商业化战略，涵盖乳腺癌、结直肠癌、前列腺癌、卵巢癌、冠状动脉疾病和2型糖尿病，这是一项同类首创的测试，可以在发病前预测高达70％的年度死亡率和发病率。最近，该公司对胰腺癌、黑色素瘤和心房颤动的评估已获得全国检测机构协会（NATA）的批准在澳大利亚销售。Genetic Technologies还与澳大利亚最大的私立医院网络Healthscope的成员黄金海岸私立医院（GCPH）签署了精准医疗试点协议。另外，该公司最近还宣布，已向一群著名的国内和国际研究和慈善组织发放了医学研究未来基金（MRFF）基因组学健康未来使命补助金。这笔拨款将为CASSOWARY试验提供资金：一项随机对照试验，研究全科医生中多癌症多基因风险评分的临床效用和成本效益。GTG是试验的国家研究合作伙伴。
About Knightscope, Inc.
关于 Knightscope, Inc.
Knightscope is an advanced public safety technology company that builds fully autonomous security robots and blue light emergency communications systems that help protect the places people live, work, study and visit. Knightscope's long-term ambition is to make the United States of America the safest country in the world. Learn more about us at .
Knightscope是一家先进的公共安全技术公司，致力于制造全自主安全机器人和蓝光应急通信系统，以帮助保护人们生活、工作、学习和参观的地方。Knightscope的长期目标是使美利坚合众国成为世界上最安全的国家。要了解更多关于我们的信息，请访问。
About Soligenix, Inc.
关于 Soligenix, Inc.
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With a successful Phase 3 study completed, regulatory approval is being sought and commercialization activities for this product candidate are being advanced initially in the U.S. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation including pediatric Crohn's disease (SGX203).
Soligenix是一家处于后期阶段的生物制药公司，专注于开发和商业化用于治疗医疗需求未得到满足的罕见疾病的产品。我们的专业生物治疗业务部门正在开发Hybryte（SGX301 或合成金丝桃素钠），并朝着潜在的商业化方向发展，这是一种利用安全可见光治疗皮肤T细胞淋巴瘤（CTCL）的新型光动力疗法。随着一项3期研究的成功完成，该候选产品的商业化活动正在寻求监管部门的批准，该候选产品的商业化活动正在美国初步推进。该业务领域的开发计划还包括将合成金丝桃素（SGX302）扩展到牛皮癣、我们的同类首创先天防御调节剂（IDR）技术、用于治疗炎症性疾病（包括头颈部癌的口腔粘膜炎制剂）的杜斯克肽（SGX942）以及口服倍氯米司的专利用于预防的17,21-二丙酸酯 (BDP) 的松/治疗以严重炎症为特征的胃肠道（GI）疾病，包括小儿克罗恩氏病（SGX203）。
Our Public Health Solutions business segment includes active development programs for RiVax, our ricin toxin vaccine candidate, as well as our vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, our vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA).
我们的公共卫生解决方案业务部门包括RivaX的积极开发计划，我们的蓖麻毒素候选疫苗，以及我们针对丝状病毒（例如马尔堡和埃博拉）的疫苗计划以及我们预防 COVID-19（由 SARS-CoV-2 引起）的候选疫苗 civaX。我们的疫苗项目开发采用了我们专有的热稳定平台技术，即 ThermoVax。迄今为止，该业务领域得到了国家过敏和传染病研究所（NIAID）、国防威胁减少局（DTRA）和生物医学高级研究与发展局（BARDA）的政府补助和合同资金的支持。
For further information regarding Soligenix, Inc., please visit the Company's website at
有关 Soligenix, Inc. 的更多信息，请访问该公司的网站
About Genetic Technologies Limited
关于基因技术有限公司
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products. For more information, please visit .
基因技术有限公司（澳大利亚证券交易所股票代码：GTG；纳斯达克：GENE）是一家多元化的分子诊断公司。凭借其GeneType和easyDNA品牌，成为健康、保健和严重疾病领域基于基因组学的检测领域的全球领导者。GTG提供癌症预测测试和评估工具，以帮助医生改善世界各地人们的健康状况。该公司拥有一个专有的风险分层平台，该平台是在过去十年中开发的，该平台整合了临床和遗传风险，为医生和个人提供可行的结果。Genetic Technologies在肿瘤、心血管和代谢疾病的风险预测方面处于世界领先地位，继续开发风险评估产品。欲了解更多信息，请访问。
About RedChip Companies
关于红筹公司
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 30 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, the RedChip Small Stocks Big Money Show is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, "The RedChip Small Stocks Big Money Show," which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
RedChip Companies是一家Inc. 5000公司，是一家专注于微型股和小型股公司的国际投资者关系、媒体和研究公司。30年来，RedChip为其客户提供了具体、可衡量的结果。我们的时事通讯《RedChip Small Stocks Big Money Show》每周在线向6万名投资者发布。RedChip为微型股和小型股公司开发了业内最全面的服务平台。这些服务包括：股票研究的全球分销网络；美国主要城市的零售和机构路演；股票经纪商、区域投资协议、机构和家族办公室的境外营销；产生数百万独特投资者观点的数字媒体投资者关系平台；投资者网络研讨会和群组电话会议；每周在美国彭博社播出的电视节目 “红筹小股大额资金秀”；本地和全国市场的电视广告；公司产品和视频；网站设计；以及传统投资者关系服务，包括撰写新闻稿、撰写投资者简报、撰写季度电话会议剧本、战略咨询、融资等。
To learn more about RedChip's products and services, please visit:
要了解有关RedChip产品和服务的更多信息，请访问：
"Discovering Tomorrow's Blue Chips Today"
“今天发现明天的蓝筹股”
Follow RedChip on LinkedIn:
在领英上关注 RedChip：
Follow RedChip on Facebook:
在脸书上关注 RedChip：
Follow RedChip on Instagram:
在 Instagram 上关注 RedChip
Follow RedChip on Twitter:
在推特上关注 RedChip：
Follow RedChip on YouTube:
在 YouTube 上关注 RedChip
Follow RedChip on Rumble:
在 Rumble 上关注 RedChip：
Subscribe to our Mailing List:
订阅我们的邮件列表：
Contact:
联系人：
Dave Gentry
RedChip Companies Inc.
1-800-RED-CHIP (733-2447)
Or 407-491-4498
info@redchip.com
戴夫·金特里
RedChip Companies
1-800-RED-CHIP (733-2447)
或 407-491-4498
info@redchip.com
SOURCE: RedChip
来源： redChip